Mainz Biomed B.V. (MYNZ)
USD 2.85
(-4.53%)
USD 2.85
(-4.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -26.29 Million USD | 0.59% |
| 2022 | -26.45 Million USD | -119.12% |
| 2021 | -12.07 Million USD | -1262.29% |
| 2020 | -886.17 Thousand USD | 24.57% |
| 2019 | -1.17 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | -5.18 Million USD | 17.72% |
| 2023 Q1 | -6.63 Million USD | 18.98% |
| 2023 FY | -26.29 Million USD | 0.59% |
| 2023 Q2 | -8.25 Million USD | -24.38% |
| 2023 Q3 | -6.29 Million USD | 23.66% |
| 2022 Q4 | -8.18 Million USD | -46.32% |
| 2022 Q1 | -5.66 Million USD | 50.44% |
| 2022 Q3 | -5.59 Million USD | 19.35% |
| 2022 FY | -26.45 Million USD | -119.12% |
| 2022 Q2 | -6.93 Million USD | -22.51% |
| 2021 Q1 | -39.99 Thousand USD | 72.74% |
| 2021 FY | -12.07 Million USD | -1262.29% |
| 2021 Q4 | -11.42 Million USD | -291.04% |
| 2021 Q3 | -2.92 Million USD | -1113.91% |
| 2021 Q2 | -240.75 Thousand USD | -502.0% |
| 2020 Q1 | -146.72 Thousand USD | 38.68% |
| 2020 FY | -886.17 Thousand USD | 24.57% |
| 2020 Q4 | -146.72 Thousand USD | 0.0% |
| 2020 Q3 | -146.72 Thousand USD | 0.0% |
| 2020 Q2 | -146.72 Thousand USD | 0.0% |
| 2019 Q4 | -239.26 Thousand USD | 0.0% |
| 2019 FY | -1.17 Million USD | 0.0% |
| 2019 Q1 | -239.26 Thousand USD | 0.0% |
| 2019 Q2 | -239.26 Thousand USD | 0.0% |
| 2019 Q3 | -239.26 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 70.281% |
| Biodesix, Inc. | -52.14 Million USD | 49.573% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -231.305% |
| Castle Biosciences, Inc. | -57.46 Million USD | 54.241% |
| DarioHealth Corp. | -59.42 Million USD | 55.751% |
| Exact Sciences Corporation | -204.14 Million USD | 87.119% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 103.112% |
| Illumina, Inc. | -1.16 Billion USD | 97.735% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -158.899% |
| iSpecimen Inc. | -11.09 Million USD | -136.909% |
| Standard BioTools Inc. | -74.65 Million USD | 64.777% |
| 23andMe Holding Co. | -666.7 Million USD | 96.056% |
| Medpace Holdings, Inc. | 282.81 Million USD | 109.298% |
| NeoGenomics, Inc. | -87.96 Million USD | 70.108% |
| Inotiv, Inc. | -105.14 Million USD | 74.99% |
| Psychemedics Corporation | -4.15 Million USD | -533.022% |
| Prenetics Global Limited | -62.72 Million USD | 58.077% |
| Precipio, Inc. | -5.85 Million USD | -349.269% |
| RadNet, Inc. | 3.04 Million USD | 963.854% |
| Sotera Health Company | 51.37 Million USD | 151.183% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -1598.69% |
| Exagen Inc. | -23.68 Million USD | -11.004% |
| Natera, Inc. | -434.8 Million USD | 93.952% |
| Aspira Women's Health Inc. | -16.69 Million USD | -57.554% |
| Neogen Corporation | -9.42 Million USD | -179.118% |
| Myriad Genetics, Inc. | -112 Million USD | 76.522% |
| ICON Public Limited Company | 612.33 Million USD | 104.294% |
| Bionano Genomics, Inc. | -232.49 Million USD | 88.69% |
| CareDx, Inc | -190.28 Million USD | 86.181% |
| Check-Cap Ltd. | -17.56 Million USD | -49.68% |
| Twist Bioscience Corporation | -208.72 Million USD | 87.402% |
| Guardant Health, Inc. | -479.44 Million USD | 94.515% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -900.201% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 84.331% |
| Sera Prognostics, Inc. | -36.24 Million USD | 27.444% |
| OPKO Health, Inc. | -188.86 Million USD | 86.077% |
| Personalis, Inc. | -108.29 Million USD | 75.719% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -164.357% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -1598.69% |
| MDxHealth SA | -43.1 Million USD | 38.989% |
| Prenetics Global Limited | -62.72 Million USD | 58.077% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -161.382% |
| Trinity Biotech plc | -24.01 Million USD | -9.483% |
| Neuronetics, Inc. | -30.18 Million USD | 12.896% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -231.305% |